Key result
Adding hs-cTnT, NT-proBNP, and hs-CRP to the PESI risk score did not clinically improve 6-month mortality risk stratification in elderly patients with PE (NRI 0.101; 95% CI -0.099-0.302; P=0.321).
Why the study?
Combining hs-cTnT, NT-proBNP, and hs-CRP may improve risk stratification of patients with pulmonary embolism beyond the PESI risk score.
Does combining hs-cTnT, NT-proBNP, and hs-CRP with the PESI risk score improve risk stratification for 6-month mortality in elderly patients with acute pulmonary embolism?
Cohort (n=214)
Yes
Does combining hs-cTnT, NT-proBNP, and hs-CRP with the PESI risk score improve risk stratification for 6-month mortality in elderly patients with acute pulmonary embolism?
In elderly patients with submassive pulmonary embolism, the PESI risk score alone adequately predicts 6-month mortality, and the addition of cardiac and inflammatory biomarkers does not provide clinically relevant incremental prognostic value.
Answers are grounded in this paper and cite their sources.
PESI suffices for 6-month mortality stratification in elderly PE; leaves open whether biomarkers add value in other settings or endpoints.
BACKGROUND: Combining high-sensitivity cardiac Troponin T (hs-cTnT), NT-pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hs-CRP) may improve risk stratification of patients with pulmonary embolism (PE) beyond the PESI risk score. METHODS: In the prospective multicentre SWITCO65+ study, we analysed 214 patients ≥ 65 years with a new submassive PE. Biomarkers and clinical information for the PESI risk score were ascertained within 1 day after diagnosis. Associations of hs-TnT, NT-proBNP, hs-CRP and the PESI risk score with the primary endpoint defined as 6-month mortality were assessed. The discriminative power of the PESI risk score and its combination with hs-cTnT, NT-proBNP and hs-CRP for 6-month mortality was compared using integrated discrimination improvement (IDI) index and net reclassification improvement (NRI). RESULTS: Compared with the lowest quartile, patients in the highest quartile had a higher risk of death during the first 6 months for hs-cTnT (adjusted HR 10.22; 95% CI 1.79-58.34; P = 0.009) and a trend for NT-proBNP (adjusted HR 4.3; 95% CI 0.9-20.41; P = 0.067) unlike hs-CRP (adjusted HR 1.97; 95% CI 0.48-8.05; P = 0.344). The PESI risk score (c-statistic 0.77 (95% CI 0.69-0.84) had the highest prognostic accuracy for 6-month mortality, outperforming hs-cTnT, NT-proBNP and hs-CRP (c-statistics of 0.72, 0.72, and 0.54), respectively. Combining all three biomarkers had no clinically relevant impact on risk stratification when added to the PESI risk score (IDI = 0.067; 95% CI 0.012-0.123; P = 0.018; NRI = 0.101 95% CI -0.099-0.302; P = 0.321). CONCLUSIONS: In elderly patients with PE, 6-month mortality can adequately be predicted by the PESI risk score alone.
No takes yet. Share an insight, caveat, or question.
Klingenberg et al. (2019) conducted a cohort in pulmonary embolism (n=214). Addition of hs-cTnT, NT-proBNP, and hs-CRP to the PESI risk score vs. PESI risk score alone was evaluated on 6-month mortality (NRI 0.101, 95% CI -0.099-0.302, p=0.321). Adding hs-cTnT, NT-proBNP, and hs-CRP to the PESI risk score did not clinically improve 6-month mortality risk stratification in elderly patients with PE (NRI 0.101; 95% CI -0.099-0.302; P=0.321).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: